Summary
Tumor response to first-line chemotherapy in advanced breast cancer offers prognostic information and may be used as a surrogate marker for evaluating treatment efficacy. With this study we wanted to determine whether changes in circulating serum CA 15-3 levels during chemotherapy provided additional information for prognostic prediction. Serum CA 15-3 was measured at baseline and after 3 and 6 months during anthracycline-based first-line chemotherapy in 526 patients with advanced breast cancer prospectively enrolled in five phase II-III trials. Changes in marker levels were correlated with disease response, time to progression and overall survival. In all, 336 patients attained a disease response. A significant relationship was found between disease response and CA 15-3 variations, although many individual discrepancies were also observed. At the 6-month time point, the median time to progression was 15.3 months in patients with normal marker levels throughout the study, 11.7 months in those with a CA15-3 reduction >25%, 9.6 months in those with elevated baseline CA 15-3 levels which did not change during therapy and 8.6 months in those with increased marker levels (p < 0.001). The median survival was 42.3, 29.7, 28.5, and 24.8 months, respectively (p < 0.002). The prognostic role of changes in CA 15-3 levels was maintained in the patient subset attaining disease response or stabilization to treatment (p < 0.001) and after adjusting for clinical response and major prognostic parameters in the multivariate analysis (p < 0.001). In conclusion, monitoring serum CA 15-3 levels during first-line chemotherapy in advanced breast cancer patients provides prognostic information independently from tumor response.
Article PDF
Avoid common mistakes on your manuscript.
References
De Angelis R, Capocaccia R, Verdecchia A. 1997 Estimating relative survival of Italian cancer patients from sparse cancer registries data.Tumori83:33–38
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. 2000 Prognostic factors in breast cancer. College of American Pathologist Consensus Statement 1999 Arch Pathol Lab Med 124:966–978
Isaacs C, Stearns V, Hayes DF. 2001 New prognostic factors for breast cancer recurrenceSemin Oncol 28:53–67
Clark GM, Sledge GW, Kent Osborne C, McGuire WL. 1987 Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patientsJ Clin Oncol 5:55–61
Miller AB, Hogestraeten B, Staquet M, Winkler A. 1981 Reporting results of cancer treatmentCancer 47:207–214
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MT, Gwyther SG. 2000 New guidelines to evaluate the response to treatment in solid tumorsJ Natl Cancer Inst 92:205–216
Pierga JY, Robain M, Jouve M, Asselain B, Dieras V, Beuzeboc P, Palangie T, Dorval T, Extra JM, Scholl S, Pouillart T. 2001 Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patientsAnn Oncol 12:231–237
Bruzzi P. 2002 Objective response to treatment as a potential surrogate marker of survival in breast cancerAnn NY Acad Sci 963:144–147
Anderson JR, Cain KC, Gelber RD. 1983 Analysis of survival by tumor responseJ Clin Oncol 1:710–719
Del Mastro L, Sormani MP, Venturini M, Bastholt L, Bastit P, Brufman G, Focan C, Fountzilas G, Marschner N, Rosso R, Bruzzi P. 2002 Tumor response as surrogate end-point for survival in metastatic breast cancer patients: a meta-analysis [abstract]Ann Oncol 13(Suppl 3):15
Stearns V, Yamauchi H, Hayes DF. 1998 Circulating tumor markers in breast cancer: accepted utilities and novel prospectsBreast Cancer Res Treat 52:239–259
Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vignati G, Fortunato A, Saracchini S, Biasioli R, Giulisano M. 1994 Evaluation of critical differences of CEA and CA 15-3 levels in serial samples from patients operated for breast cancerInt J Biol Markers 9:135–139
Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L. 1997 Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic diseaseBr J Cancer 75:698–702
Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW. 1988 Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancerCancer Res 48:4107–4112 Jul 15
Depres-Brummer P, Itzhaki M, Bakker PJ, Hoek FJ, Veenhof KH, de Wit R. 1995 The usefulness of CA 15-3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancerJ Cancer Res Clin Oncol 121:419–422
Soletormos G, Nielsen D, Schioler V, SkovsgaardT, Dombernowsky P. 1996 Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-upClin Chem 42:564–575
Sjostrom J, Alfthan H, Joensuu H, Stenman UH, Lundin J, Blomqvist C. 2001 Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancerScand J Clin Lab Invest 61:431–441
Einarsson R, Lindman H, Bergh J. 2000 Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patientsAnticancer Res 20:5089–5093
Cheung KL, Graves CR, Robertson JF. 2000 Tumour marker measurements in the diagnosis and monitoring of breast cancerCancer Treat Rev 26:91–102
Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2001 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical OncologyJ Clin Oncol 19:1865–1878
Kallioniemi OP, Oksa H, Aaran RK, Hietanen T, Lehtinen N, Koivula T. 1988 Serum CA 15-3 assay in the diagnosis and follow-up of breast cancerBr J Cancer 58:213–215
Alabiso O, Durando A, Malossi A, Capello C, Martinotti R, Katsaros D, Genta F. 1998 A first-line therapy in metastatic breast cancer (MBC) with paclitaxel (T) and epidoxorubicin (E) regimen. A Phase I-II study [abstract]Tumori 84(Suppl 1):119
Bumma C, Dogliotti L, Ciambellotti E, Botta M, Narcisi M, Gosso P, D’Arrigo A, Berruti A, Perroni D, Lauria G, Grecchi␣LG: 5-fluorouracil, epirubicin, cyclophosphamide (FEC) vs. epirubicin in advanced breast cancer. In: Proceedings of ECCO 5, 1989; London, September 3–7, 1989
Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Tampellini M, Durando A, Destefanis M, Monzeglio C, Moro G, Sussio M, Perroni D. 1996 Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trialJ Clin Oncol 30:1165–1172
Dogliotti L, Danese S, Berruti A, Zola P, Buniva T, Bottini A, Richiardi G, Moro G, Farris A, Bau MG, Porcile G. 1998 Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot studyCancer Chemother Pharmacol 41:333–338
Berruti A, Bitossi R, Gorzegno G, Bottini A, Durando A, De Matteis A, Nuzzo F, Giardina G, Danese S, De Lena M, Lorusso V, Farris A, Sarobba MG, DeFabiani E, Bonazzi G, Castiglione F, Bumma C, Moro G, Bruzzi P, Dogliotti L. 2002 Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addiction of either cisplatin or lonidamine: final results of a phase III study with a factorial designJ Clin Oncol 20:4150–4159
Harrell FE Jr., Lee KL, Califf RM, Pryor DB, Rosati RA. 1984 Regression modelling strategies for improved prognostic predictionStat Med 3:143–152
Nie NH, Hull CH, Jeakins JG, Steinbrenner K, Bent Dh. 1988 Statistical package for the social sciences SPSS, Chicago
Hortobagyi GN. 1998 Treatment of breast cancerN Engl J Med 339:974–984
Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Busdar AU, Hortobagyi GN. 2001 Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyondThe Oncologist 6:133–146
Conte P, Gennari A, Landucci E, Guarneri V, Donati S, Salvadori B, Bengala C, Orlandini C. 2001 New combinations with epirubicin in advanced breast cancerOncology (Huntingt) 15(Suppl 7):24–27
Kiang DT, Greenberg LJ, Kennedy BJ. 1990 Tumor marker kinetics in the monitoring of breast cancerCancer 65:193–199
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tampellini, M., Berruti, A., Bitossi, R. et al. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Breast Cancer Res Treat 98, 241–248 (2006). https://doi.org/10.1007/s10549-005-9155-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-005-9155-y